Alimera Sciences/ALIM

$3.52

-8.57%
-
1D1W1MYTD1YMAX

About Alimera Sciences

Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.

Ticker

ALIM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Eiswirth

Employees

159

Headquarters

Alpharetta, United States

Alimera Sciences Metrics

BasicAdvanced
$196.33M
Market cap
-
P/E ratio
-$2.16
EPS
1.20
Beta
-
Dividend rate
$196.33M
1.19927
$4.38
$1.56
81.68K
2.392
2.307
139.677
140.098
-0.19%
-20.53%
-697.34%
-29.94%
2.431
4.252
49.19%
16.57%
16.69%

What the Analysts think about Alimera Sciences

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
127.27% upside
High $10.00
Low $6.00
$3.52
Current price
$8.00
Average price target

Alimera Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-14.06% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$26.3M
12.88%
Net income
$-3.7M
184.62%
Profit margin
-14.06%
152.42%

Alimera Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.71
-$1.32
-$0.06
-$0.07
-
Expected
-$0.32
$0.02
-$0.06
$0.00
-$0.07
Surprise
121.88%
-8,900%
-6.98%
-∞%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Alimera Sciences stock?

Alimera Sciences (ALIM) has a market cap of $196.33M as of April 13, 2024.

What is the P/E ratio for Alimera Sciences stock?

The price to earnings (P/E) ratio for Alimera Sciences (ALIM) stock is 0 as of April 13, 2024.

Does Alimera Sciences stock pay dividends?

No, Alimera Sciences (ALIM) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Alimera Sciences dividend payment date?

Alimera Sciences (ALIM) stock does not pay dividends to its shareholders.

What is the beta indicator for Alimera Sciences?

Alimera Sciences (ALIM) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Alimera Sciences stock price target?

The target price for Alimera Sciences (ALIM) stock is $8, which is 127.27% above the current price of $3.52. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Alimera Sciences stock

Buy or sell Alimera Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing